India's NovaLead Pharma Repurposes Off-the-Shelf Drugs for COVID-19, an Industrial Info Market Brief
India's NovaLead Pharma Repurposes Off-the-Shelf Drugs for COVID-19, an Industrial Info Market Brief
Attachment: India
Indian drug discovery and research company, NovaLead Pharma Private Limited, is set to trial its repurposed COVID-19 drug, which is code-named NLP21. The company claims the drug has shown better efficacy than all the other existing treatments currently being used in the treatment of COVID-19.
The country's top drug regulator, Drug Controller General of India (DCGI), has recently granted approval to NovaLead "in principle" to undertake clinical trials for its repurposed drug.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- France Plans $55 Billion in Windfarms as Offshore Projects Gain Momentum
- Africa's Fertilizer Demand Sparks $5.8 Billion of Projects
- Poland's PGE Plans $7 Billion Renewable Energy Push
- Peru's Runoff Presidential Election Could Impact $45 Billion in Mining Proj...
- Industrial Construction Activity Up 37% So Far in 2021